Christina Aguilera Is the Latest Xeomin Brand Partner

By ·
Christina Aguilera Is the Latest Xeomin Brand Partner featured image

Announced today, Christina Aguilera is the newest partner with Xeomin, the anti-wrinkle injection that is FDA-approved to temporarily improve the appearance of frown lines.

“Something that stood out to me about Xeomin is the transparency about the ingredients in the treatment along with the natural-looking results,” says the singer-songwriter and all-around global icon. “Being a ‘smart tox’ that treats my frown lines with only the ingredients that work and none that don’t is important to me and validates my confidence in the treatment.”

As part of the brand’s ‘Beauty on Your Terms’ multi-channel campaign, Aguilera joins other celebrity partners to encourage women and men to, as the name suggests, “embrace beauty on their own terms.”

“I’ve always been candid about self-confidence and encourage everyone to embrace their own version of themselves,” she continues. “Part of my journey to embracing and taking care of my best self is being intentional about the products I use and the ingredients in them. That’s why I want to use a smart tox for frown lines that has only the ingredients essential for treatment. As a performer, I need to be able to express myself, and Xeomin gives me a natural look that I love.”

“As one of the most powerful and iconic voices of our time, Christina Aguilera personifies our ‘Beauty on Your Terms’ mission,” said Patrick Urban, Merz Aesthetics president, North America, in a release. “Our trailblazing marketing collaborations have reached a new audience. With the U.S. aesthetics market expanding at a rapid pace among adult Gen Z and millennials, we’re focused on empowering women and men with the freedom to make the aesthetic choices that help them maintain their self-confidence.”

Related Posts

Find a Doctor

Find a NewBeauty "Top Beauty Doctor" Near you

Give the Gift of Luxury

NewBeauty uses cookies for various reasons, including to analyze and improve its content and advertising. Please review our Privacy Policy and Terms of Use for more about how we use this data. By continuing to use this site, you agree to these policies.